Matthew E Korenberg Ligand Pharmaceuticals Inc (LGND) insider trading activity

Matthew E Korenberg is President & COO of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 50,777 shares of LGND, which is worth approximately $5.78 Million. The most recent transaction as insider was on Sep 23, 2024, when has been sold 9,772 shares (Common Stock) at a price of $101.24 per share, resulting in proceeds of $989,317. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50.8K

0% 3M change

47.73% 12M change

Total Value Held $5.78 Million

Matthew E Korenberg Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 23 2024	SELL Open market or private sale	$989,317 $101.24 p/Share	9,772 Reduced 16.14%	50,777 Common Stock
Sep 23 2024	BUY Exercise of conversion of derivative security	$502,476 $51.42 p/Share	9,772 Added 13.9%	60,549 Common Stock
Sep 20 2024	SELL Open market or private sale	$653,227 $104.1 p/Share	6,275 Reduced 11.0%	50,777 Common Stock
Sep 20 2024	BUY Exercise of conversion of derivative security	$249,050 $49.99 p/Share	4,982 Added 8.03%	57,052 Common Stock
Sep 16 2024	SELL Payment of exercise price or tax liability	$337,470 $105.0 p/Share	3,214 Reduced 5.81%	52,070 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	$325,018 $56.29 p/Share	5,774 Added 9.66%	54,008 Common Stock
Aug 26 2024	SELL Open market or private sale	$1,203,475 $105.67 p/Share	11,389 Reduced 18.7%	49,510 Common Stock
Aug 23 2024	SELL Open market or private sale	$660,298 $104.61 p/Share	6,312 Reduced 9.39%	60,899 Common Stock
Aug 22 2024	SELL Open market or private sale	$122,109 $105.54 p/Share	1,157 Reduced 1.69%	67,211 Common Stock
Aug 09 2024	SELL Open market or private sale	$1,797,132 $98.5 p/Share	18,245 Reduced 21.06%	68,368 Common Stock
Jun 28 2024	BUY Other acquisition or disposition	$21,248 $60.71 p/Share	350 Added 0.4%	86,613 Common Stock
May 14 2024	SELL Open market or private sale	$1,208,810 $85.38 p/Share	14,158 Reduced 14.1%	86,263 Common Stock
May 13 2024	SELL Open market or private sale	$290,817 $84.54 p/Share	3,440 Reduced 3.31%	100,421 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	14,416 Added 12.19%	103,861 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$356,677 $74.65 p/Share	4,778 Reduced 5.07%	89,445 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$210,928 $72.31 p/Share	2,917 Reduced 3.0%	94,223 Common Stock
Dec 05 2023	SELL Payment of exercise price or tax liability	$118,266 $59.61 p/Share	1,984 Reduced 2.0%	97,140 Common Stock
Jun 30 2023	BUY Other acquisition or disposition	$21,349 $56.78 p/Share	376 Added 0.38%	99,124 Common Stock
Feb 23 2023	BUY Grant, award, or other acquisition	-	9,069 Added 8.41%	98,748 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$210,912 $72.98 p/Share	2,890 Reduced 3.12%	89,679 Common Stock
Dec 28 2022	SELL Payment of exercise price or tax liability	$255,813 $66.29 p/Share	3,859 Reduced 4.0%	92,569 Common Stock
Dec 13 2022	BUY Grant, award, or other acquisition	-	14,000 Added 12.68%	96,428 Common Stock
Nov 30 2022	SELL Payment of exercise price or tax liability	$261,929 $72.9 p/Share	3,593 Reduced 4.18%	82,428 Common Stock
Nov 01 2022	BUY Grant, award, or other acquisition	-	27,714 Added 24.37%	86,021 Common Stock
Jun 30 2022	BUY Other acquisition or disposition	$12,438 $75.84 p/Share	164 Added 0.31%	52,532 Common Stock

Also insider at

QLGN

Qualigen Therapeutics, Inc. Healthcare

Director

LNDC

LANDEC CORP \CA\ Healthcare

Director

PIRS

PIERIS PHARMACEUTICALS, INC. Healthcare

CFO, Treasurer

MEK